Oncology

COVID-19 and HIV reshaped cancer care, leading to delayed screenings, a surge in telehealth, mental health strain, and equity lessons, many of which clinicians still confront.

Experts explore the complexities of cannabis use, the financial impact, and best practices for administration in patients with cancer.

In the first-cycle of chemotherapy, patients under 40 were more likely to have higher rates of nausea/vomiting.

Historically, 30% to 60% of AYA patients with cancer experience sexual dysfunction.

Erin Baurle, PsyD, discussed sleep-wake disturbances in patients with cancer and the efficacy of a CBT-I pilot program.

Ben Brewer, PsyD, discussed the 5 core components of cognitive behavioral therapy for insomnia.

Persistent training and workflow gaps were listed as potential barriers of AYA care among oncologists.

In each decade since the launch of the journal ONCOLOGY, cancer care has evolved, and with it the finances and costs associated with these improving treatments.

Julian Hong, MD, MS, stated that the demand for highly specialized teams trained to combat the onset of mental health disorders outpaces the supply.

Julian Hong, MD, MS, discussed an analysis showing that patients with cancer and new mental health disorders have an increased risk of all-cause mortality.

According to a study published in Cancer, new-onset mental health disorders increased the risk of all-cause mortality in patients with cancer.

Over the past 40 years, oncology shifted to precision care, smarter toxicity management, AI-guided guidelines, and equity, according to Julie Gralow, MD.

As the journal ONCOLOGY reaches it's 40-year anniversary, it's important to reflect on the transformation of cancer care in that time, according to Julie M. Vose, MD, MBA, and Neil M. Iyengar, MD.

Zolucatetide yielded a DCR of 100% and ORR of 80% among patients with secretase-naive and secretase-treated desmoid tumors.

Daniel C. McFarland, DO, and Boris Kiselev, MD, highlight the need for oncologists to recognize and address depression for patients with cancer.

Several differences arise between community oncology centers and institutional oncology centers regarding the tools available and requirements of patients with cancer.

Often, patients in middle-income settings, are the patients who are impacted most by insurance deductibles, according to Loretta Nastoupil, MD.

Experts review strategies for effective screening and other measures for limiting cancer incidence in observance of National Cancer Prevention Month.

Loretta Nastoupil, MD, reflected on some of the differences between practicing in a rural, community cancer center compared with a larger institutional center.

Development of the oral DHX9 inhibitor, ATX-559, has been halted following adverse events in a phase 1/2 trial of patients with metastatic solid tumors.

Vanessa Almendro Navarro, PhD, MBA, outlined what she hopes to accomplish in her new role as chief commercialization officer at City of Hope.

Experts convene at the 2025 MCL Scientific Consortium to spark collaborations, advance novel therapies, and boost patient outcomes through foundation-driven research support.

This section aims to enhance provider empathy, mitigate burnout, and center the patient’s lived experience within the rigorous framework of medical science.

Vanessa Almendro-Navarro, PhD, MBA, discussed her background as a fellow at Dana-Farber, as well as her experience as a life science executive.

Updated results from the TRIDENT-1 trial support repotrectinib as a new treatment option for those with NTRK fusion-positive advanced solid tumors.